Use of Oral and Emergency Contraceptives After the US Supreme Court's Dobbs Decision.


Journal

JAMA network open
ISSN: 2574-3805
Titre abrégé: JAMA Netw Open
Pays: United States
ID NLM: 101729235

Informations de publication

Date de publication:
03 Jun 2024
Historique:
medline: 26 6 2024
pubmed: 26 6 2024
entrez: 26 6 2024
Statut: epublish

Résumé

The US Supreme Court Dobbs v Jackson Women's Health Organization decision allowed states to strengthen restrictions on abortion access, triggering the closure of family planning clinics and leading to confusion about the legality of emergency contraceptives (ECs). To evaluate the association between the Dobbs decision and fills for oral and emergency contraceptives in states that enacted the most restrictive abortion policies after Dobbs. This cohort study used data on contraceptive fills for women of reproductive age (15-49 years) in the US from IQVIA's National Prescription Audit PayerTrak and data from the Guttmacher Institute were used to categorize changes in abortion restrictions in each state. A difference-in-differences analysis compared changes in monthly fill rates for daily oral contraceptive pills (OCPs) and ECs in states that became most restrictive (implemented a full abortion ban after Dobbs) and comparison states (kept a medium level of abortion restrictions after Dobbs) before (March 2021 to November 2021) and after (July 2022 to October 2023) the Dobbs decision. State-level abortion restrictions. Monthly fills of OCPs and ECs per 100 000 women of reproductive age. Between March 2021 and October 2023, 142.8 million prescriptions for OCPs and 904 269 prescriptions for ECs were dispensed at US retail pharmacies. Before Dobbs, trends in monthly fill rates were similar for OCPs and ECs between the most restrictive and comparison states. After the Dobbs decision, states that became the most restrictive experienced an additional 4.1% decline in OCP fills with 285.9 fewer fills per 100 000 (95% CI, -495.8 to -6.8; P = .04). In contrast to OCPs, fills for ECs increased during the first year after Dobbs (July 2022 to June 2023) in both groups of states. However, 1 year after Dobbs (July 2023 to October 2023), the most restrictive states experienced an additional 65% decrease in emergency contraceptive fills with 13.2 fewer fills per 100 000 (95% CI, -27.2 to -4.1; P = .01). In this cohort study of prescriptions filled at US pharmacies, the Dobbs decision was associated with declines in oral contraceptives, particularly ECs, in states enacting the most restrictive abortion policies. Given the important role of OCPs and ECs in preventing pregnancy and the need for abortion, efforts to improve access may be needed, especially in states where legal abortion is no longer an option.

Identifiants

pubmed: 38922616
pii: 2820370
doi: 10.1001/jamanetworkopen.2024.18620
doi:

Substances chimiques

Contraceptives, Postcoital 0
Contraceptives, Oral 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

e2418620

Auteurs

Dima M Qato (DM)

Program on Medicines and Public Health, Alfred Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles.
Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.

Rebecca Myerson (R)

Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
Department of Population Health Sciences, University of Wisconsin, Madison.

Andrew Shooshtari (A)

Program on Medicines and Public Health, Alfred Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles.

Jenny S Guadamuz (JS)

Division of Health Policy and Management, University of California at Berkeley School of Public Health, Berkeley.

G Caleb Alexander (GC)

Department of Epidemiology at the Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.
Center for Drug Safety and Effectiveness, Johns Hopkins Bloomberg School of Public Health, Baltimore, Maryland.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH